期刊
DRUGS OF THE FUTURE
卷 32, 期 9, 页码 788-798出版社
PROUS SCIENCE, SA
DOI: 10.1358/dof.2007.032.09.1138229
关键词
-
Telaprevir is an investigational oral hepatitis C virus (HCV) protease inhibitor in phase 11 evaluation in combination with pegylated interferon and ribavirin for the treatment of chronically infected patients wit genotype 1 hepatitis C. Interim results from a phase 11 trial indicated that this drug has the potential to shorten the duration of treatment for some patients with genotype 1 HCV. Additional phase 11 trials involve the treatment of patients who have failed previous interferon-based treatment, as well as treatment in the absence of ribavirin.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据